As IGH::BCL2 translocation occurs in approximately 20%–30% of patients with de novo DLBCL and results in BCL2 overexpression, which is associated with a poor prognosis of DLBCL, we investigated whether BCL2 induces SOX9 expression in specific DLBCL subsets. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.